Danuta Owczarek

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 277 citations

Immunology, Clinical Trials, Gastroenterology +7

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin et al. · Gastroenterology · 2023 · 86 citations · Full text

Proinflammatory cytokines in the saliva of patients with active and non-active Crohn's disease

Katarzyna Szczeklik, Danuta Owczarek, Jolanta Pytko-Polończyk et al. · Polskie Archiwum Medycyny Wewnętrznej · 2012 · 67 citations · Full text

Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2α (8-iso-PGF2α) level in patients with inflammatory bowel diseases

Danuta Owczarek, Dorota Cibor, Tomasz Mach · Inflammatory Bowel Diseases · 2009 · 64 citations · Full text

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

David T. Rubin, Jessica R. Allegretti, Julián Panés et al. · The Lancet · 2024 · 62 citations · Full text

Placebo-controlled Induction, Gastroenterology, Pathology +6